Scopia Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LivaNova
LIVN
|
+$33.6M |
| 2 |
UnitedHealth
UNH
|
+$29.9M |
| 3 |
TSMC
TSM
|
+$22.5M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$22.4M |
| 5 |
Chemours
CC
|
+$15.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DraftKings
DKNG
|
+$31M |
| 2 |
Valvoline
VVV
|
+$22.5M |
| 3 |
Mercury Systems
MRCY
|
+$20.7M |
| 4 |
Dollar Tree
DLTR
|
+$20.6M |
| 5 |
AerCap
AER
|
+$11.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 31.54% |
| 2 | Consumer Discretionary | 25.34% |
| 3 | Healthcare | 14.17% |
| 4 | Materials | 12.43% |
| 5 | Technology | 9.93% |
Similar funds
Scopia Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Scopia Capital Management held 35 positions worth $819M, up 18% from $692M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Scopia Capital Management deployed $81.6M of net new capital in Q2 2025, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was LivaNova: 814,243 shares worth $36.7M.
By sector, the portfolio is most concentrated in Industrials at 32% of assets, down from 37% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Valvoline, an estimated $22.5M trimmed.
- Scopia Capital Management's largest Q2 2025 buy was LivaNova: 814,243 shares worth $36.7M.
- Scopia Capital Management added most to Chemours in Q2 2025, an estimated $15.8M increase.
- Scopia Capital Management's biggest Q2 2025 reduction was Valvoline, cutting an estimated $22.5M.
- Scopia Capital Management fully exited DraftKings in Q2 2025, selling an estimated $31M.
- Scopia Capital Management's ten largest holdings make up 58% of its $819M portfolio in Q2 2025.
- Scopia Capital Management opened 13 new positions and closed 3 in Q2 2025.
- Scopia Capital Management's portfolio value rose 18% quarter-over-quarter to $819M.
Based on Scopia Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.